Abbott Laboratories (ABT) Stock Price, Quote & News

Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement th...

Industry: Medical Devices

Sector: Healthcare

Phone: 224 667 6100

Website: www.abbott.com

Address:

100 Abbott Park Road, Abbott Park, United States

traderheadnyc Feb. 24 at 2:12 AM

$ABT i got me few shares of this

0 · Reply

BlushTrade Feb. 23 at 11:58 PM

TODAY’S TRADE RECAP 🚨 ✅ $ABT 115 Call (2/27) — +80% 💰🔥 ✅ $SPY | 686 — +35% 💰 ✅ $SPY | 683 — +751% 🏦🔥 ✅ $KMI 34 Call (2/27) — +22% 📈 Consistent wins. Real results. Real profits.

0 · Reply

d_risk Feb. 23 at 8:34 PM

$ABT - Abbott Laboratories - 10K - Updated Risk Factors Abbott adds execution and financing risks from the $22.9B, debt-funded Exact Sciences deal and consolidates global risks into broader geopolitical, macroeconomic, cost containment, and climate/public-health disruption exposures, while trimming standalone COVID-specific and international-operations risk breakouts. #Healthcare #MergersAndAcquisitions #FinancingRisk #GeopoliticalRisk #MacroeconomicRisk 🟢 Added 🟠 Removed https://d-risk.ai/ABT/10-K/2026-02-20

0 · Reply

ChartSniper33 Feb. 22 at 6:08 PM

$ABT dumpy?

1 · Reply

ZacksResearch Feb. 20 at 3:44 PM

$BSX vs. $ABT — clear winner in MedTech right now? Abbott edges out Boston Scientific with stronger valuation appeal, solid CGM momentum, and strategic deals that strengthen its investment case. That combo gives it the upper hand in this matchup. 📈 Want to see the full comparison before making your move? Dive in here 👉 https://www.zacks.com/stock/news/2872780/bsx-vs-abt-which-medtech-stock-is-the-better-investment-now?cid=sm-stocktwits-2-2872780-teaser-34410&ADID=SYND_STOCKTWITS_TWEET_2_2872780_TEASER_34410

0 · Reply

ZacksResearch Feb. 20 at 2:44 PM

$ABT vs. $BSX: Which MedTech Giant Offers More Value? 🤔 Abbott's diversified growth and strategic acquisition of Exact Sciences position it well in the high-growth cancer diagnostics market. Despite tariff pressures, Abbott's adjusted gross and operating margins improved in Q4. Discover why ABT might be the smarter pick right now 👉 https://www.zacks.com/stock/news/2872780/bsx-vs-abt-which-medtech-stock-is-the-better-investment-now?cid=sm-stocktwits-2-2872780-body-34409&ADID=SYND_STOCKTWITS_TWEET_2_2872780_BODY_34409

0 · Reply

Mergerbrief Feb. 20 at 1:10 PM

$EXAS / $ABT – Shareholder Vote EXAS

0 · Reply

ZacksResearch Feb. 20 at 11:16 AM

$SENS integrates Eversense 365 with twiist AID system — is this a game-changer? 🤔 📈 Eversense 365 offers up to 365 days of wear time, far surpassing competitors like $DXCM and $ABT's 15-day max. 🚀 Shares rise 0.5% after-hours potentially due to the announcement of the news yesterday. Discover the full story here 👉 https://www.zacks.com/stock/news/2872623/sens-eversense-365-integrated-with-twiist-gains-full-availability?cid=sm-stocktwits-2-2872623-body-34335&ADID=SYND_STOCKTWITS_TWEET_2_2872623_BODY_34335

0 · Reply

JInvestTrade Feb. 20 at 4:13 AM

$SENS $DXCM $TNDM $ABT https://www.linkedin.com/posts/sequel-med-tech_sequel-med-tech-and-senseonics-launch-transformative-activity-7430263714454388736-rncD?utm_medium=ios_app&rcm=ACoAACZifW0B2JqOqHkWvrhyPzzcI0ENdA47TYM&utm_source=social_share_send&utm_campaign=copy_link

0 · Reply

JInvestTrade Feb. 20 at 4:08 AM

$SENS $DXCM $PODD $TNDM $ABT https://www.linkedin.com/posts/eversense-cgm_eversense365-eversensecgm-diabetes-activity-7430271018340024322-zPai?utm_medium=ios_app&rcm=ACoAACZifW0B2JqOqHkWvrhyPzzcI0ENdA47TYM&utm_source=social_share_send&utm_campaign=copy_link

0 · Reply

Exact Sciences Stockholders Approve Acquisition by Abbott

EXAS

Feb 20, 2026, 11:38 AM EST - 4 days ago

Abbott declares 409th consecutive quarterly dividend

Feb 17, 2026, 11:32 AM EST - 7 days ago

Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key

Feb 15, 2026, 6:08 PM EST - 8 days ago

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

ALKT CDNA CWAN DKNG DT ESTA EXAS

Feb 12, 2026, 8:05 AM EST - 12 days ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ADBE AMGN AVGO BAC BK BMY

Feb 6, 2026, 8:00 AM EST - 18 days ago

Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation

Feb 4, 2026, 10:49 AM EST - 20 days ago

Abbott recalls glucose sensors after seven deaths linked to faulty readings

Feb 2, 2026, 9:30 AM EST - 22 days ago

Abbott: Long-Term Investment Opportunity For Dividend Growth Investors

Jan 29, 2026, 10:10 AM EST - 26 days ago

10 Highest Rated Dividend Kings For Generations Of Income

ABBV ABM ADM BDX BKH KMB KO

Jan 25, 2026, 10:11 PM EST - 4 weeks ago

Best Dividend Kings: January 2026

ABBV ABM ADM ADP AWR BDX BKH

Jan 25, 2026, 8:00 AM EST - 4 weeks ago

Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy

Jan 24, 2026, 7:30 AM EST - 4 weeks ago

Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity

Jan 23, 2026, 9:35 AM EST - 4 weeks ago

Is The Fall In Abbott Stock Justified?

Jan 23, 2026, 7:25 AM EST - 4 weeks ago

Abbott Laboratories: Buy This Dividend King On Sale Now

Jan 23, 2026, 6:43 AM EST - 4 weeks ago

Abbott faces India scrutiny in cough syrup abuse investigation, documents show

Jan 22, 2026, 2:31 PM EST - 4 weeks ago

Abbott Laboratories Raised Prices, Prompting Sales Slump

Jan 22, 2026, 12:54 PM EST - 4 weeks ago

Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript

Jan 22, 2026, 12:02 PM EST - 4 weeks ago

Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results

Jan 22, 2026, 11:00 AM EST - 4 weeks ago

MRNA Rallies on Cancer Vaccine Trial, PG Mixed Earnings, ABT Sell-Off

MRNA PG

Jan 22, 2026, 9:53 AM EST - 4 weeks ago

Cramer's Mad Dash: Abbott Labs

Jan 22, 2026, 9:48 AM EST - 4 weeks ago

Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints

Jan 22, 2026, 7:49 AM EST - 4 weeks ago

Abbott Stock Slumps on Earnings. What's Weighing on the Medical Devices Maker.

Jan 22, 2026, 7:34 AM EST - 4 weeks ago

Abbott misses quarterly revenue estimates on weakness in diagnostics segment

Jan 22, 2026, 7:30 AM EST - 4 weeks ago

Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

Jan 22, 2026, 2:02 AM EST - 4 weeks ago

Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q4 Earnings

Jan 21, 2026, 3:53 AM EST - 4 weeks ago

Polen Focus Growth Portfolio Q4 2025 Performance, Attribution & Portfolio Activity

AAPL AMZN GOOG GOOGL ISRG IWB IWF

Jan 20, 2026, 9:00 AM EST - 5 weeks ago

Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms

Jan 19, 2026, 7:30 AM EST - 5 weeks ago

Abbott Laboratories: Q4 Earnings On The Horizon

Jan 7, 2026, 9:17 AM EST - 6 weeks ago

Abbott: Not Cheap, But Built To Compound In Uncertain Markets

Jan 7, 2026, 8:00 AM EST - 6 weeks ago

Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy

Jan 5, 2026, 4:30 PM EST - 7 weeks ago

Abbott hosts conference call for fourth-quarter earnings

Jan 5, 2026, 9:05 AM EST - 7 weeks ago

Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions

Dec 31, 2025, 8:47 AM EST - 7 weeks ago

Best Dividend Aristocrats For January 2026

ABBV ADM ADP AFL ALB AMCR AOS

Dec 28, 2025, 6:44 AM EST - 2 months ago

Best Dividend Kings: December 2025

ABBV ABM ADM ADP AWR BDX BKH

Dec 26, 2025, 10:35 PM EST - 2 months ago

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

CVX KMB ABM AMGN AVGO BCPC BEN

Dec 24, 2025, 10:00 AM EST - 2 months ago

Abbott Laboratories Shrugs Off Tariffs And China Headwinds With A 7% Dividend Raise

Dec 22, 2025, 9:00 AM EST - 2 months ago

Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation

Dec 18, 2025, 9:00 AM EST - 2 months ago

Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart

Dec 12, 2025, 10:26 AM EST - 2 months ago

Abbott increases quarterly dividend for 54th consecutive year

Dec 11, 2025, 3:45 AM EST - 2 months ago

High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth

AI ASND AXON AZO CPRT DXCM HOOD

Dec 8, 2025, 9:00 AM EST - 2 months ago

Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data

Dec 6, 2025, 8:45 PM EST - 2 months ago

University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives

Dec 4, 2025, 11:00 AM EST - 2 months ago

Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement

Nov 29, 2025, 8:02 AM EST - 3 months ago

Best Dividend Aristocrats For December 2025

ABBV ADM ADP AFL ALB AMCR AOS

Nov 24, 2025, 11:08 AM EST - 3 months ago

Abbott issues US device correction for some glucose monitors over faulty readings risk

Nov 21, 2025, 8:30 PM EST - 3 months ago

Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS

EXAS

Nov 20, 2025, 9:37 AM EST - 3 months ago

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics

EXAS

Nov 20, 2025, 8:43 AM EST - 3 months ago

Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test

EXAS

Nov 20, 2025, 7:46 AM EST - 3 months ago

Abbott to Acquire Exact Sciences for $21 Billion

EXAS

traderheadnyc Feb. 24 at 2:12 AM

$ABT i got me few shares of this

0 · Reply

BlushTrade Feb. 23 at 11:58 PM

0 · Reply

d_risk Feb. 23 at 8:34 PM

0 · Reply

ChartSniper33 Feb. 22 at 6:08 PM

$ABT dumpy?

1 · Reply

ZacksResearch Feb. 20 at 3:44 PM

0 · Reply

ZacksResearch Feb. 20 at 2:44 PM

0 · Reply

Mergerbrief Feb. 20 at 1:10 PM

$EXAS / $ABT – Shareholder Vote EXAS

0 · Reply

ZacksResearch Feb. 20 at 11:16 AM

0 · Reply

JInvestTrade Feb. 20 at 4:13 AM

0 · Reply

JInvestTrade Feb. 20 at 4:08 AM

0 · Reply

Napoliblue Feb. 20 at 4:00 AM

$CDIO yes they made a comparison Abbott Laboratories $ABT bought Cologuard for $21 Billion from $EXAS Cologuard started around August 2014 when it received FDA approval and began being offered to patients through healthcare providers. So it took nine years to get bought out. CDIO has been around only 3 years and their test kits for heart disease is expanding in Africa, India, Japan and Australia. BOTTOM LINE FUTURE LOOKS BRIGHT Specific segments (like cardiovascular drugs) are forecast to reach hundreds of billions by the early 2030s. The company has growing pains but once they turn the corner it’s gonna be worth the investment. Heart Disease is the number killer Globally. I’m holding long term with size .

0 · Reply

Broview Feb. 20 at 3:30 AM

$ABT spin off please? Zero focus?

0 · Reply

cubie Feb. 19 at 9:57 PM

$ABT sure is 😅 but $NFLX $UNH abt is no comparison to software bear whales. holy cow. look at big softie $MSFT and $INTU

2 · Reply

Estimize Feb. 19 at 5:15 PM

Wall St is expecting 1.15 EPS for $ABT Q1 [Reporting 04/22 BMO] http://www.estimize.com/intro/abt?chart=historical&metric_name=eps&utm_cont

0 · Reply

Steward59 Feb. 17 at 3:20 PM

$ABT fixed at 112?

0 · Reply

Lynnaasa Feb. 17 at 2:45 PM

$ABT 112.80 pre +0.12% under 50DMA 119.58, I’m short, boring bleed

0 · Reply

1212JM Feb. 16 at 3:53 PM

$ABT $125

0 · Reply

PolycarpFX Feb. 16 at 2:29 AM

$ABT

1 · Reply

Woodman7 Feb. 14 at 4:22 PM

$ABT

1 · Reply

Woodman7 Feb. 14 at 4:18 PM

$ABT - check $EXAS recent earnings release. $ABT caught a diamond in the rough for cheap. 23% growth in 4Q25! That oughta spark a little bit of growth in 2026 and beyond

1 · Reply

Woodman7 Feb. 14 at 4:16 PM

$ABT Exact Sciences Corporation - Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2026/Exact-Sciences-Announces-Record-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx

0 · Reply

Market Cap	195.12B
Revenue (ttm)	44.33B
Net Income (ttm)	6.52B
EPS (ttm)	N/A
PE Ratio	21.78
Forward PE	19.76
Profit Margin	14.72%
Debt to Equity Ratio	0.25

Volume	9,017,126
Avg Vol	9,563,206
Day's Range	N/A - N/A
Shares Out	1.74B
Stochastic %K	100%
Beta	0.75
Analysts	Strong Sell
Price Target	$134.38